Refine by
Retinopathy Articles & Analysis
30 news found
Globally, 146 million people are currently living with diabetic retinopathy (DR), which can develop into a more serious condition which is diabetic macular edema. ...
ByBayer AG
The primary endpoint of this study is to document change in BCVA, as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score, from the date of randomization through 36 weeks of treatment. ...
ByBayer AG
Globally, 146 million people are currently living with diabetic retinopathy (DR), which can develop into a more serious condition which is diabetic macular edema (DME). ...
ByBayer AG
Globally, 146 million people are currently living with diabetic retinopathy (DR), which can develop into a more serious condition which is diabetic macular edema (DME). ...
ByBayer AG
Globally, 146 million people are currently living with diabetic retinopathy (DR), which can develop into a more serious condition which is diabetic macular edema (DME). ...
ByBayer AG
IDx-DR, Digital Diagnostics’ flagship product, detects more than mild diabetic retinopathy (including macular edema) at the point-of-care proving a diagnosis when disease is present. ...
“At Bayer, we recognize that families with premature babies with retinopathy of prematurity are waiting for new effective and well tolerated treatment options to spare them from significant visual impairment and even blindness,” said Dr. ...
ByBayer AG
Globally, 146 million people are currently living with diabetic retinopathy (DR), which can develop into a more serious condition which is diabetic macular edema (DME). ...
ByBayer AG
Valo Health, Inc. (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that dosing has commenced in its Phase 2 study — a multi-center ...
With suprachoroidal administration of axitinib, there is the potential to achieve prolonged duration and targeted delivery to affected tissue layers to potentially treat VEGF-driven disorders such as wet AMD, diabetic macular edema and diabetic retinopathy. About Clearside’s SCS Microinjector® Clearside’s patented, proprietary suprachoroidal space (SCS®) ...
CORALVILLE, IOWA July 26, 2022 – Digital Diagnostics is proud to announce a partnership with ArchWell Health to bring IDx-DR, the autonomous AI diagnostic system for the detection of diabetic retinopathy (DR) – including diabetic macular edema (DME) – to ArchWell Health centers across the United States. ...
CORALVILLE, IOWA July 21, 2022 – Leadership from Digital Diagnostics – maker of IDx-DR, the first-ever FDA-cleared, fully autonomous AI system for the diagnosis of diabetic retinopathy – signed a memorandum of understanding (MOU) with the Kingdom of Saudi Arabia’s Ministry of Investment during a ceremonial visit with United States of America President Joe ...
Joshi recently traveled to Malawi, Kenya, Nigeria, and Ghana as part of his efforts to commercialize ASPIRE, his device for the detection and diagnosis of malarial retinopathy. While in Africa, he met with leaders in government, philanthropy, and health care to better understand the stakeholder landscape and map out needs and priorities—in short, the path ...
As demonstrated in preclinical studies, Bcl-xL is highly expressed in diseased blood vessels during retinopathy, which have been shown to engage pathways of cellular senescence. ...
” About UBX1325 UBX1325 is an investigational compound being studied for age-related diseases of the eye, including diabetic macular edema (DME), wet age-related macular degeneration (wAMD), and diabetic retinopathy (DR) that is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis ...
About UBX1325 UBX1325 is an investigational compound being studied for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR) that is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis regulating proteins. ...
Digital Diagnostics created IDx-DR, the autonomous AI diagnostic system for the detection of diabetic retinopathy (including diabetic macular edema) at the point-of-care. Only 15% of people with diabetes receive the recommended annual diabetic eye exam.[1],[2] Access to effective diagnostic services is an obstacle, especially in rural or underserved areas. ...
” About UBX1325 UBX1325 is an investigational compound being studied for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR) that is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis regulating ...
Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat ...
Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat ...